NeuroPace to Participate in Upcoming Healthcare Conferences in September

Rhea-AI Summary

NeuroPace (Nasdaq: NPCE), a medical device company focused on epilepsy treatment, has announced its participation in two major healthcare conferences this September. The company will:

• Attend the Wells Fargo 2024 Healthcare Conference on September 4 in Boston, hosting one-on-one investor meetings
• Present at the Morgan Stanley 22nd Annual Global Healthcare Conference from September 4-6 in New York

At the Morgan Stanley conference, CEO Joel Becker and CFO Rebecca Kuhn will participate in a fireside chat on September 6 at 8:30am ET, which will be webcast live. They will also host one-on-one investor meetings. A replay of the fireside chat will be available on NeuroPace's Investor website.

News Market Reaction – NPCE

+12.98%

1 alert

+12.98% News Effect

On the day this news was published, NPCE gained 12.98%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

MOUNTAIN VIEW, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in two healthcare conferences in September. NeuroPace management will host one-on-one meetings with investors at the Wells Fargo 2024 Healthcare Conference, on Wednesday, September 4 in Boston, MA.

NeuroPace will also present at the Morgan Stanley 22^nd Annual Global Healthcare Conference, which takes place September 4-6, in New York, NY. Joel Becker, Chief Executive Officer, and Rebecca Kuhn, Chief Financial Officer, will participate in a fireside chat discussion on Friday, September 6 at 8:30am ET, and host one-on-one meetings with investors during the conference. The fireside chat will be accessible via a live webcast here and a replay will be available in the Events section of NeuroPace’s Investor website at https://investors.neuropace.com/news-and-events/events.

About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com

FAQ

What conferences will NeuroPace (NPCE) attend in September 2024?

NeuroPace will participate in the Wells Fargo 2024 Healthcare Conference on September 4 in Boston and the Morgan Stanley 22nd Annual Global Healthcare Conference from September 4-6 in New York.

When is NeuroPace's (NPCE) fireside chat at the Morgan Stanley conference?

NeuroPace's fireside chat at the Morgan Stanley conference is scheduled for Friday, September 6, 2024, at 8:30am ET.

Who will represent NeuroPace (NPCE) at the Morgan Stanley conference?

Joel Becker, Chief Executive Officer, and Rebecca Kuhn, Chief Financial Officer, will represent NeuroPace at the Morgan Stanley conference.

How can investors access NeuroPace's (NPCE) fireside chat at the Morgan Stanley conference?

Investors can access the fireside chat via a live webcast, with a replay available in the Events section of NeuroPace's Investor website at https://investors.neuropace.com/news-and-events/events.